Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
| In millions, except per share items | Jun-30-14 | Jun-30-13 | Jun-30-12 | Jun-30-11 | Jun-30-10 | Jun-30-09 | Jun-30-08 |
| | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Medical Diagnostics | | | | 0.2 | | | |
| Government Contracting | | | | 0.3 | | | |
| Total revenues | 0.2 | 0.3 | 0.6 | 0.4 | 0.0 | 2.5 | 2.5 |
| Revenue growth | -35.4% | -43.7% | 32.1% | | -100.0% | 0.1% | |
| Cost of goods sold | 1.0 | 0.0 | 0.3 | 0.4 | 0.0 | 1.3 | 1.4 |
| Gross profit | -0.8 | 0.3 | 0.3 | 0.0 | 0.0 | 1.1 | 1.1 |
| Gross margin | -369.6% | 100.0% | 54.2% | 8.0% | | 46.2% | 43.9% |
| Selling, general and administrative | 0.9 | 2.0 | 2.1 | 1.8 | 0.3 | 2.1 | 4.9 |
| Research and development | | | | 0.0 | | 0.2 | 0.0 |
| Other operating expenses | -1.0 | | 0.2 | 0.1 | | 0.3 | 0.3 |
| EBITDA [+] | -0.6 | -1.7 | -2.0 | -1.7 | | -1.2 | -3.8 |
| EBITDA growth | -63.0% | -15.1% | 13.3% | 435.6% | -72.6% | -68.7% | |
| EBITDA margin | -287.1% | -500.7% | -332.1% | -387.2% | | -47.9% | -153.1% |
| Depreciation | 0.0 | 0.0 | 0.0 | 0.0 | | | 0.0 |
| EBITA | -0.6 | -1.7 | -2.0 | -1.7 | -0.3 | -1.2 | -3.8 |
| EBITA margin | -296.0% | -505.2% | -332.8% | -387.5% | | -47.9% | -154.9% |
| Amortization of intangibles | | | | 0.1 | | 0.3 | 0.3 |
| EBIT [+] | -0.6 | -1.7 | -2.0 | -1.8 | -0.3 | -1.5 | -4.2 |
| EBIT growth | -62.2% | -14.5% | 9.8% | 453.9% | -78.5% | -63.7% | |
| EBIT margin | -296.0% | -505.2% | -332.8% | -400.4% | | -61.0% | -168.0% |
| Non-recurring items [+] | | | 0.2 | 1.2 | | | |
| Asset impairment | | | 0.2 | 1.2 | | | |
| Interest income, net [+] | -0.5 | -0.2 | 0.0 | 0.0 | | 0.7 | 0.0 |
| Interest expense | 0.5 | 0.2 | 0.0 | 0.0 | | | 0.0 |
| Interest income | | | | 0.0 | | 0.7 | |
| Other income (expense), net [+] | 1.1 | 1.9 | 2.2 | 0.0 | | 0.0 | 0.0 |
| Gain (loss) on debt retirement | -1.3 | -0.1 | | | | | |
| Other | | | | 0.0 | | | |
| Pre-tax income | 0.0 | 0.0 | 0.0 | -2.9 | -0.3 | -0.8 | -4.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -2.0 |
| Tax rate | | | | 0.0% | 0.0% | 0.0% | 48.3% |
| Minority interest | | 0.0 | 0.0 | 0.0 | | | |
| Earnings from continuing ops | -2.5 | -2.3 | -2.1 | -3.0 | -0.3 | -0.8 | -5.0 |
| Earnings from discontinued ops | | | | | | -2.2 | 11.9 |
| Net income | -2.5 | -2.3 | -2.1 | -3.0 | -0.3 | -3.0 | 6.8 |
| Net margin | -1162.1% | -700.0% | -346.0% | -663.0% | | -121.2% | 276.3% |
| |
| Basic EPS [+] | ($0.60) | ($2.53) | ($0.02) | ($0.03) | $0.00 | ($0.04) | ($0.25) |
| Growth | -76.1% | 14836.6% | -43.6% | 581.0% | -89.2% | -84.0% | |
| Diluted EPS [+] | ($0.60) | ($2.53) | ($0.02) | ($0.03) | $0.00 | ($0.04) | ($0.25) |
| Growth | -76.1% | 14836.6% | -43.6% | 581.0% | -89.2% | -84.0% | |
| |
| |
| Shares outstanding (basic) [+] | 4.1 | 0.9 | 121.5 | 99.4 | 73.8 | 19.5 | 19.8 |
| Growth | 348.0% | -99.2% | 22.1% | 34.7% | 278.7% | -1.3% | |
| Shares outstanding (diluted) [+] | 4.1 | 0.9 | 121.5 | 99.4 | 73.8 | 19.5 | 19.8 |
| Growth | 348.0% | -99.2% | 22.1% | 34.7% | 278.7% | -1.3% | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|